Letter of Intent (LOI) Application Guidelines
CLL Global Research Foundation
CLL Global Research Foundation (CLL Global) is a non-profit organization committed to accelerating progress towards the control and cure of chronic lymphocytic leukemia (CLL) and related leukemias and lymphomas. The organization facilitates the development of effective diagnostic, monitoring, and therapeutic tools for the management of CLL and related disorders. CLL Global intends to fast-track the funding process and speed the development of new therapies while focusing on ideas that can impact the clinic within two to three years.
Patients and families provide funding and participate as organization decision-makers. CLL Global is classified as a public charity and is exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code.
Key Dates
Phase
Call for Applications
LOI Submission Deadline
Notification of Full Application Invitation
Full Application Submission Deadline
Notification of Award
Award Start Date
Date
April 25, 2025
May 23, 2025
July 2025
October 10, 2025
December 2025
April 2026
Eligibility
Individuals with an M.D., Ph.D. or equivalent degree are eligible to be invited to submit an application. Applicants must be affiliated with an accredited academic center or research institute (domestic or foreign). Individuals must have demonstrated experience in CLL research as well as an adequate research environment. An application may have collaborators from multiple institutions. In any given funding cycle, an individual may be the principal investigator on only one application.
2025 Research Priorities
As part of our ongoing commitment to advancing the treatment and understanding of chronic lymphocytic leukemia (CLL), we invite researchers to align their applications with the following research priorities:
- BTK and BCL-2 Inhibitor Refractory Disease
Investigate mechanisms of resistance and explore novel strategies to overcome refractory disease. - Richter Transformation
Advance our understanding of the biology, diagnosis, and treatment of Richter transformation. - Immune Dysfunction and Restoration
Examine the causes of immune dysregulation in CLL and develop approaches to restore immune function. - Novel Therapeutic Targets and Approaches
Identify and validate new molecular targets and innovative treatment strategies for CLL.
Please ensure your submission clearly addresses one or more of these priorities. Proposals that demonstrate high potential for clinical impact and innovation are strongly encouraged.
Review Process
Letters of Intent will be reviewed by independent reviewers and the CLL Global Scientific Advisory Board who will make recommendations to the Board of Directors. The Board of Directors will make the final selection of applications to be invited to submit a full proposal. Applications will be evaluated on their relevance to the defined research priorities, strength of the scientific rationale, and likelihood to lead to advances in treatment, diagnosis, or monitoring of CLL in the near-term. Applicants will be notified via email as to whether they have been selected to submit a full application.
Completing the LOI
The following information is required to complete the application form:
- General information including the project title, name of the Principal Investigator (PI), recipient institution address, and PI contact information.
- Selection of the primary research priority that the proposal addresses. Only one priority may be selected.
- The amount of funding requested up to $100,000.
- Status of IRB or IACUC approval as appropriate.
- PI biographical sketch using the standard NIH format.
- A scientific abstract (500 words) that address the working hypothesis, scientific rationale, experimental design, and expected outcomes.
Considerations
- Awards are for a period of 12 months with a budget up to $100,000. This amount is inclusive of up to 5% that may be used for institutional overhead.
- Funds may not be used for secretarial or office expenses.
- Co-investigators are permitted.
- Reviewers’ comments are considered confidential.